Transcode Therapeutics (RNAZ) Operating Income (2020 - 2026)

Transcode Therapeutics (RNAZ) has reported Operating Income for 7 consecutive years, with -$6.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Income fell 60.85% year-over-year to -$6.8 million; the trailing twelve-month figure through Jun 2026 stood at -$45.1 million (down 208.07% YoY), and the FY2025 full-year result was -$28.0 million, down 78.66% from the prior year.
• Operating Income improved to -$6.8 million in Q2 2026 per RNAZ's latest filing, from -$17.8 million in the prior quarter.
• Across five years, Operating Income topped out at -$2.2 million in Q3 2024 and bottomed at -$17.8 million in Q1 2026.
• Historically, Operating Income has averaged -$5.9 million across 5 years, with a median of -$4.9 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Operating Income tumbled 1224.03% in 2022, then surged 59.22% in 2024.
• Over 5 years, Operating Income stood at -$5.5 million in 2022, then gained by 25.44% to -$4.1 million in 2023, then decreased by 24.28% to -$5.1 million in 2024, then plunged by 214.72% to -$16.0 million in 2025, then jumped by 57.64% to -$6.8 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered -$6.8 million, -$17.8 million, and -$16.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.